Portal de Periódicos da CAPES

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

2012; BioMed Central; Volume: 5; Issue: 1 Linguagem: Inglês

10.1186/1756-8722-5-12

1756-8722

Véronique Gelsi‐Boyer, Mandy Brecqueville, Raynier Devillier, Anne Murati, Julien Mozziconacci, Daniel Birnbaum,

Chronic Myeloid Leukemia Treatments

The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies should help in prognosis assessment.